| |
The SRI International Digest #1, Fall 2001
In This Issue:
WELCOME TO THE FIRST EDITION OF THE "SRI DIGEST"
You're reading the first edition of the quarterly "SRI Digest" from SRI
International, the independent, nonprofit research institute. SRI International
helps its clients succeed by providing innovative solutions to important
problems in information and engineering technologies; pharmaceuticals and
biotechnology; chemistry and physics; and education, health, and economic
development. The SRI Digest will help keep you informed about recent SRI innovations, which may suggest ways that SRI can help you create value.
ARTIFICIAL INTELLIGENCE ADVANCES BIOLOGY RESEARCH
As reported in the September 14, 2001 edition of Science, SRI has developed
novel software that uses artificial intelligence and symbolic computing
to better understand and manipulate genome data. "Pathway Tools" encodes
complex scientific theories, leading to a greater understanding of biological
systems and improved scientific collaboration. The software forms the basis
of the EcoCyc Project, a symbolic pathway
database funded by the National Institutes of Health.
More info
SRI TECHNOLOGIES FOR NATIONAL SECURITY
SRI works with government and business clients to develop technologies for physical, information, and biological security. Our work includes innovations such as radar, network security software, explosive containment devices, battlefield simulation software for training, and more.
More info on radar
More info on explosives
More info on biological
and chemical sensors
See also these pages for information security
CHAMELEON TELECOM TRANSFORMS FIBER-OPTIC NETWORKS
SRI recently announced Chameleon Telecom, a matchbook-sized tunable laser
architecture for fiber-optic networks that allows tunable laser technology
to be deployed at one-tenth of the size and cost of conventional technologies.
Chameleon Telecom is available for licensing.
More info
ADVANCES IN CANCER RESEARCH & DRUG DEVELOPMENT
SRI scientists are investigating an exciting new concept in cancer therapy:
targeting tumor blood vessels, rather than just tumor cells themselves,
with anti-cancer drugs. In addition to investigating how to target tumor vessels, SRI scientists are involved in determining how to target another unique property of solid tumors: hypoxia (oxygen deficiency). The presence of significant levels of hypoxia in tumors presents a unique strategy for anticancer drug therapy with the design of agents that aim at these hypoxic fractions of tumors. With this idea in mind, SRI, in collaboration with Stanford University, has developed Tirapazamine, a promising drug targeting the hypoxic fractions of tumors, now in late-stage clinical trials.
HOT TECHNOLOGIES FOR SALE
SRI actively seeks licensing partnerships and acquisitions of its discoveries.
For our current portfolio, visit http://www.sri.com/rd/hot.html,
and contact us at bizdev@sri.com.
ABOUT SRI INTERNATIONAL:
SRI is celebrating its 55th year as the "soul of Silicon Valley". SRI introduced
the computer mouse and the foundations of personal computing in 1968, received
the first wireless Internet transmission in 1977, developed life-saving
cardiovascular drugs in the 1980s, and designed revolutionary speech recognition
systems in the 1990s. SRI International, a nonprofit corporation, was founded
as Stanford Research Institute in 1946, and has been independent since 1970. Visit us online!
CONTACT US:
For more information on SRI's innovations and how we can help you, contact
bizdev@sri.com.
The SRI Digest welcomes your feedback. Please send suggestions or comments
to newsletter@sri.com.
Previous Issues
|
|
R&D Divisions